ClinicalTrials.gg
CompletedNCT03935607Updated Apr 20, 2022

The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index

An observational study in Oligohydramnios, sponsored by Rambam Health Care Campus. Completed at 1 site in Israel. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-04-20.

Sponsored by Rambam Health Care Campus · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The current study is based on the use of transvaginal sonography in the evaluation of oligohydramnios. Patients will be recruited after amniotic fluid index evaluation according to transabdominal sonography. After obtaining informed consent, transvaginal sonography will be used to evaluate and measure a possible amniotic fluid pocket that may precede the fetal presenting part.

Read the detailed description

Background Normal amniotic fluid volume varies across gestation (Ounpraseuth 2017). Abnormal amniotic fluid volume has been associated with a variety of adverse pregnancy outcomes (Shrem 2016). In clinical practice, the amniotic fluid volume is a component of the biophysical profile which provides information on fetal well-being.

Transabdominal ultrasound is used to assess quantitatively the amniotic fluid volume, most commonly by either the Amniotic Fluid Index (AFI) or the Maximum Vertical Pocket (MVP) methods.

The value of the AFI method has been questioned in several studies, which have shown that an abnormal test, low or high, is neither highly accurate nor predictive of adverse outcome. Many pregnancies with normal AFI will be falsely characterized as abnormal, and a large number with truly abnormal AFI will be missed (Magann 1994, Chauhan 1997).

The MVP measurement may be preferred over the AFI method. A 2008 systematic review of randomized trials found that use of the AFI increased the rate of diagnosis of oligohydramnios (RR 2.3), induction of labor (RR 2.1), and cesarean delivery for fetal distress (RR 1.5) (Nabhan 2008).

Rationale and Hypothesis of the Study Recently, our group observed that when transvaginal ultrasound is being performed to non-laboring pregnant women at term for other obstetrical indications, there is a large amniotic fluid pocket above the internal cervical os and below the fetal presenting part. Due to the unique location of this pocket, we hypothesized that transvaginal ultrasound may provide better information than transabdominal ultrasound on amniotic fluid volume, particularly in cases when suspecting abnormal low amniotic fluid volume.

Data Collection

  1. Maternal and fetal characteristics Data related to the fetomaternal antenatal, intrapartum and postpartum course will be recorded prospectively.
  2. Ultrasound assessment Each eligible woman in the study population group will be asked to undergo prenatal ultrasound examination twice. The first ultrasound examination is a routine transabdominal ultrasound examination that is carried out to assess fetal growth and well-being. This is to be continued with a second transvaginal ultrasound, with a specific focus on the amniotic fluid pocket, that is; the distance in centimetres between the fetal presenting part and the internal cervical os. The second transvaginal ultrasound will be performed for the purpose of the study only, and by one other research team member that is blinded to the first routine transabdominal ultrasound. The entire length of the study, combining the transabdominal and transvaginal ultrasounds, is expected to take on the average around 15 min.

Ultrasound Equipment and Safety Considerations In their 2011 statement, The International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) and World Federation of Ultrasound in Medicine and Biology (WFUMB) consider ultrasonography to be safe for use during clinical practice (ISUOG 2011).

Statistical analyses and sample size For sample size calculation, and given a 20% rate of induction of labor, of which 3% are due to abnormal low amniotic fluid volume (oligohydramnios), a sample size of 1000 women is required.

Feasibility of the Study Considering the high volume of maternal care here at Rambam Health Care Campus, and that every year there are around 5,000 births and nearly double routine cares, the recruitment process for the current study is feasible.

Expected Duration of the Study The recruitment for the study is expected to take place over 12 months with an additional 3-6 months after recruitment for data analysis before publication.

Funding Women will be recruited while approaching Rambam Health Care Campus for their routine obstetric care. Ultrasound examinations will be carried out using existing operational ultrasound equipments within the obstetric department at Rambam Health Care Campus. For both, the recruitment and the ultrasound examinations, no extra funding is currently required.

Public Health Interest Identifying new ultrasound variables that can assist in quantifying amniotic fluid volume, as the one suggested in the current study, is of great importance and may provide invaluable information into the overall future care and decision-making around the time of delivery, especially whether or not to induce labor in women with suspected oligohydramnios. Thus, it may assist in creating future recommendations for pregnant women and improved healthcare standards during the delivery process.

02

Conditions studied

  • Oligohydramnios

Browse trials for

03

In context

Oligohydramnios

25 studies on the registry are indexed under Oligohydramnios; 5 are open to participants now.

Browse Oligohydramnios studies →

Lead sponsor

Rambam Health Care Campus is the lead sponsor of 466 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Women who meet the above inclusion criteria will be asked to participate in the study and to provide a written informed consent. This study, under no circumstances, will alter the participants routine care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women at term beyond 37 weeks' gestation
  • Presented to our hospital for their routine care or prior to induction of labor
  • Singleton pregnancy
  • Planned for vaginal delivery
  • Non-laboring women with non-engaged fetal presenting part

Exclusion criteria

Exclusion Criteria:

  • Pregnant women under 37 weeks' gestation
  • Planned cesarean deliveries
  • Laboring women with engaged fetal presenting part
  • Multiple gestation
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
350 participants (actual)
Patient registry
No

Groups and cohorts

  • Normal amniotic fluid index

    Patients with an amniotic fluid index of between 5-24 centimeters according to transabdominal sonography.

    Diagnostic Test: Transvaginal sonography

  • Oligohydramnios

    Patients with an amniotic fluid index of lss than 5 centimeters according to transabdominal sonography.

    Diagnostic Test: Transvaginal sonography

Interventions

  • Diagnostic testTransvaginal sonography

    Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.

06

What researchers measure

Primary outcomes

  1. Amniotic Fluid Fore-Pocket

    Measurement of amniotic fluid pocket preceding fetal presenting part.

    Time frame: Up to 30 minutes from the beginning of patient evaluation.

Secondary outcomes

  1. Mode of delivery

    Vaginal delivery, vacuum assisted delivery, cesarean section.

    Time frame: From time of induction up to 48 hours postpartum

  2. pH level

    Umbilical artery pH level

    Time frame: From the time of delivery up to 30 days postpartum

  3. 1 minute Apgar score

    Neonatal 1st minute Apgar score

    Time frame: From the time of delivery up to 30 days postpartum

  4. 5 minute Apgar score

    Neonatal 5th minute Apgar score

    Time frame: From the time of delivery up to 30 days postpartum

  5. Neonatal intensive care unit admission

    Rate of neonatal intensive care unit admission

    Time frame: From the time of delivery up to 30 days postpartum

07

Study locations

1 site
  • Rambam health care campus
    Haifa, Israel
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03935607
Responsible party
ROY LAUTERBACH MD (Principal Investigator, Rambam Health Care Campus) — Principal investigator
First posted
May 2, 2019
Start date
Jul 1, 2019
Primary completion
Dec 31, 2021
Completion
Apr 1, 2022
Last update
Apr 20, 2022

Study contacts

Roy Lauterbach, MD
principal investigator · Rambam Health Care Campus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion